Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 3—March 2022
Letter

Addendum to Proposal for Human Respiratory Syncytial Virus Nomenclature below the Species Level

On This Page
Article Metrics

Cite This Article

To the Editor: We previously proposed a nomenclature for human respiratory syncytial virus (HRSV) to standardize the sharing of viral isolates and sequences (1). This nomenclature was adopted by the World Health Organization’s Global RSV surveillance program and incorporated into the GISAID EpiRS platform (https://www.gisaid.org). One situation not covered in our proposal was when subtypes HRSV A and HRSV B coexist in the same clinical sample. Although this situation appears relatively infrequently, usually in <1% of HRSV-positive respiratory samples (2,3), some sources describe higher levels of codetection (e.g., 3.4% in a study from Senegal [4]). Dual infections may also be more frequently identified when subtype-specific PCR is introduced, as they have been in phase 2 of the World Health Organization RSV program (5,6). We offer an approach to clarify nomenclature in such instances of codetection.

We recommend that the designations in the style of HRSV/A-B/Iran/1234/2021 be used in laboratory databases. However, the most important output from these samples is likely to be the genetic sequences. We recommend separate database submissions of the consensus sequences from HRSV A and HRSV B be designated, for example, HRSV/A/Iran/1234/2021 and HRSV/B/Iran/1234/2021, each having the same metadata and noting that both sequences came from the same clinical sample. Clearly identifying dual HRSV A and B infections will enable closer monitoring and, therefore, better understanding of the true frequency of these co-occurrences, of importance because dual infections raise interesting questions about illness severity compared with infection with HRSV A or B alone, duration of protection from reinfection, and factors modulating the frequency of dual infections.

We also note that dual infections may raise technical difficulties, such as assignment of sequence reads to the correct subgroup. However, algorithms such as IRMA (image registration meta-algorithm) (7) that appear effective for sequencing approaches (e.g., Illumina, https://www.illumina.com) and long-read approaches (e.g., Oxford Nanopore, https://nanoporetech.com) might also be employed to ensure correct generation and assignment of HRSV A and B sequences from dual infections. Whereas co-infections with other respiratory pathogens are clearly recognized and well-studied, dual infections with HRSV A and B remain less so, but we are now well-positioned to identify these infections.

Top

Acknowledgment

U.J.B. was supported by the Intramural Program of the National Institute of Allergy and Infectious Diseases of the National Institutes of Health.

Top

Ian G. BarrComments to Author , Thomas C. Williams, Vahid Salimi, and Ursula J. Buchholz
Author affiliations: WHO Collaborating Centre for Reference and Research on Influenza, VIDRL, Doherty Institute, Melbourne, Victoria, Australia (I.G. Barr); University of Edinburgh, Edinburgh, Scotland, UK (T.C. Williams); Tehran University of Medical Sciences, Tehran, Iran (V. Salimi); National Institute of Allergy and Infectious Diseases, National Institutes of Health, Maryland, USA (U. Buchholz)

Top

References

  1. Salimi  V, Viegas  M, Trento  A, Agoti  CN, Anderson  LJ, Avadhanula  V, et al. Proposal for human respiratory syncytial virus nomenclature below the species level. Emerg Infect Dis. 2021;27:19. DOIPubMedGoogle Scholar
  2. Mlinaric-Galinovic  G, Tabain  I, Kukovec  T, Vojnovic  G, Bozikov  J, Bogovic-Cepin  J, et al. Analysis of biennial outbreak pattern of respiratory syncytial virus according to subtype (A and B) in the Zagreb region. Pediatr Int. 2012;54:3315. DOIPubMedGoogle Scholar
  3. Zhang  Y, Yuan  L, Zhang  Y, Zhang  X, Zheng  M, Kyaw  MH. Burden of respiratory syncytial virus infections in China: Systematic review and meta-analysis. J Glob Health. 2015;5:020417. DOIPubMedGoogle Scholar
  4. Fall  A, Dia  N, Cisse  HA, Kiori  DE, Sarr  FD, Sy  S, et al. Epidemiology and molecular characterization of human respiratory syncytial virus in Senegal after four consecutive years of surveillance, 2012–2015. PLoS One. 2016;11:e0157163. DOIPubMedGoogle Scholar
  5. Todd  AK, Costa  AM, Waller  G, Daley  AJ, Barr  IG, Deng  YM. Rapid detection of human respiratory syncytial virus A and B by duplex real-time RT-PCR. J Virol Methods. 2021;294:114171. DOIPubMedGoogle Scholar
  6. Wang  L, Piedra  PA, Avadhanula  V, Durigon  EL, Machablishvili  A, López  MR, et al. Duplex real-time RT-PCR assay for detection and subgroup-specific identification of human respiratory syncytial virus. J Virol Methods. 2019;271:113676. DOIPubMedGoogle Scholar
  7. Shepard  SS, Meno  S, Bahl  J, Wilson  MM, Barnes  J, Neuhaus  E. Viral deep sequencing needs an adaptive approach: IRMA, the iterative refinement meta-assembler. [Erratum in BMC Genomics. 2016;17:801.]. BMC Genomics. 2016;17:708. DOIPubMedGoogle Scholar

Top

Cite This Article

DOI: 10.3201/eid2803.212438

Original Publication Date: February 15, 2022

Related Links

Top

Table of Contents – Volume 28, Number 3—March 2022

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Ian Barr, WHO Collaborating Centre for Reference and Research on Influenza, Doherty Institute, Melbourne, VIC 3000, Australia

Send To

10000 character(s) remaining.

Top

Page created: January 12, 2022
Page updated: February 21, 2022
Page reviewed: February 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external